[ad_1]
CoronaVac, developed by Chinese pharmaceutical company Sinovac Biotech, was stopped on the same day that US pharmaceutical giant Pfizer reported that it tested 90 percent of the vaccine it developed. efficiency. As a result, there is growing hope that vaccination will begin soon and that the pandemic situation will improve.
Brazil’s health regulator Anvisa said in a statement that it “decided to suspend the clinical trials of the CoronaVac vaccine following a serious adverse incident” on October 29.
The authority claimed that it could not publish details of the incident due to privacy rules. However, according to representatives, such incidents include deaths, life-threatening side effects, disability, hospitalization, birth complications and other “major clinical cases.”
However, the Bhutanese Institute, the public health center that coordinates COVID-19 vaccine research in Brazil, said the decision was unexpected for them.
The institute is “thoroughly investigating what happened” and will seek “clarification from the Brazilian health regulator on any adverse incidents during clinical trials.”
No part of this publication may be reproduced without the written permission of ELTA.
[ad_2]
